Cytomel (Liothyronine) Cost in Iowa 2026

What Does Cytomel (Liothyronine) Cost in Iowa in 2026?

Generic liothyronine costs an average of $35 per month at Iowa retail pharmacies in 2026, making it one of the most affordable synthetic T3 options. Brand-name Cytomel (manufactured by Pfizer) carries a list price near $120 per month, though very few cash-pay patients pay that amount given the availability of generics and discount programs.

Liothyronine is the synthetic form of triiodothyronine (T3), the more metabolically active thyroid hormone. The FDA first approved the brand Cytomel decades ago; the current prescribing information is maintained on the FDA accessdata portal [1]. Prices vary by pharmacy chain, city, and whether a discount card is applied. Des Moines, Cedar Rapids, and Sioux City pharmacies generally cluster within a few dollars of the statewide average, though independent pharmacies sometimes quote slightly higher cash prices before a discount card is applied.

Using GoodRx or a similar pharmacy benefit manager coupon can bring a 30-day supply of generic liothyronine 25 mcg down to as little as $10 to $18 at major Iowa chains such as Hy-Vee Pharmacy, Walgreens, and CVS [2]. The FDA's generic drug program encourages this kind of competition, and the agency confirms that approved generic liothyronine products meet the same bioequivalence standards as Cytomel [1].

Patients filling a 90-day supply rather than a 30-day supply may realize an additional 10 to 15 percent cost reduction at mail-order pharmacies operating within Iowa. A clinician's prescription for a 90-day supply is required; telehealth providers serving Iowa can write this at the initial or follow-up visit.

Does Iowa Medicaid Cover Liothyronine?

Iowa Medicaid does not cover Cytomel or generic liothyronine for hypothyroidism adjunct use as of 2026. Levothyroxine (synthetic T4) is the preferred agent on the Iowa Medicaid preferred drug list because it has a longer evidence base for monotherapy, lower cost, and once-daily dosing convenience.

The American Thyroid Association's 2014 guidelines state that levothyroxine monotherapy "remains the standard of care for hypothyroidism" and note that combination T4/T3 therapy "cannot be recommended for routine treatment" based on current evidence [3]. Iowa Medicaid's formulary reflects this position. Patients who have a documented clinical reason for T3 therapy, such as persistent symptoms despite optimized levothyroxine or a rare deiodinase polymorphism affecting T4-to-T3 conversion, may request a prior authorization, but approval rates for liothyronine remain low under Iowa Medicaid.

Iowa Health Link (the managed Medicaid program) similarly excludes liothyronine from its preferred formulary. Patients enrolled in the Iowa Wellness Plan or Iowa Marketplace Choice Plan face the same restriction. If you are on Iowa Medicaid and your clinician believes liothyronine is medically necessary, ask for a prior authorization appeal with supporting lab work (free T3, free T4, TSH) and a written clinical rationale.

The National Institutes of Health notes that T3 has a significantly shorter half-life (about 24 hours) than T4 (about 7 days), which contributes to prescriber caution and insurer hesitation [4]. Divided dosing or slow-release compounded formulations are sometimes used to address this pharmacokinetic limitation.

Is Compounded Liothyronine Legal in Iowa?

Compounded liothyronine from a 503A-licensed pharmacy is legal in Iowa and costs approximately $40 per month. Iowa allows compounding pharmacies operating under Section 503A of the Federal Food, Drug, and Cosmetic Act to prepare patient-specific liothyronine formulations, including slow-release capsules that attempt to flatten the T3 concentration peak seen with immediate-release tablets [5].

The legal framework matters. A 503A pharmacy compounds for individual patients based on a valid prescription from a licensed practitioner. A 503B outsourcing facility, by contrast, produces larger batches for healthcare facilities and is subject to FDA Current Good Manufacturing Practice (CGMP) standards. Iowa patients filling compounded T3 prescriptions should confirm their pharmacy holds a valid Iowa Board of Pharmacy 503A registration.

The FDA has flagged concerns about the quality and consistency of some compounded thyroid hormone preparations [6]. A 2013 FDA safety communication warned that compounded thyroid hormone products had not been shown to be safe or effective by the agency's approval standards [6]. That does not make them illegal under 503A, but it does mean patients and prescribers should choose compounding pharmacies with strong quality testing and PCAB accreditation when possible.

Bunevicius et al. published a landmark trial in the New England Journal of Medicine (1999, N=33) showing that replacing 50 mcg of levothyroxine with 12.5 mcg of liothyronine improved mood and neuropsychological function in hypothyroid patients [7]. This trial is frequently cited to justify adjunct T3 therapy, though its small sample size limits definitive conclusions. A later replication attempt by Walsh et al. in the same journal (2003, N=101) did not reproduce the same magnitude of benefit, indicating the question remains open [8].

The Endocrine Society's 2012 clinical practice guideline on hypothyroidism in adults acknowledges that "some patients feel better with combination T4/T3 therapy" but stops short of recommending it as first-line treatment, citing the need for larger randomized controlled trials [9]. Iowa compounding pharmacies can legally prepare customized doses, such as 5 mcg or 7.5 mcg capsules, that are not available commercially.

How Does Insurance Cover Liothyronine in Iowa?

Private insurance coverage for liothyronine in Iowa varies widely. Most commercial plans place generic liothyronine on Tier 2 (preferred generic) with a copay of $10 to $25 per 30-day fill, provided the patient meets the plan's indication criteria. Brand Cytomel typically lands on Tier 3 or Tier 4, with copays ranging from $45 to $90 or higher, depending on the plan's cost-sharing design.

The major Iowa insurer network includes Wellmark Blue Cross and Blue Shield, UnitedHealthcare, Medica, and Aetna. Each plan publishes its drug formulary online, and Iowa residents can check tier placement at the insurer's website or through the Iowa Insurance Division portal [10]. A clinician's prior authorization citing lab evidence of inadequate T4 monotherapy response (persistently low free T3 with normal or suppressed TSH, for example) improves the chance of Tier 2 placement or step-therapy exception for brand Cytomel.

Medicare Part D plans sold in Iowa also vary. In 2026, several Part D formularies in Iowa cover generic liothyronine at $0 to $10 during the initial deductible phase under the Inflation Reduction Act's expanded cost-sharing caps for generic drugs [11]. Checking the Medicare Plan Finder at medicare.gov with your specific drug and dose will show the actual out-of-pocket cost for each plan in your Iowa county.

Employer self-funded plans (common in Iowa's manufacturing and agriculture sectors) may use a pharmacy benefit manager such as Express Scripts or CVS Caremark. These PBMs negotiate rebates directly with manufacturers. Generic liothyronine is usually well-covered, but the PBM's preferred pharmacy network may exclude some independent Iowa pharmacies.

What Discount Programs Are Available for Cytomel in Iowa?

Several discount mechanisms can bring liothyronine costs well below the $35 average cash price. GoodRx coupons are accepted at most Iowa retail pharmacies and consistently price generic liothyronine between $10 and $20 for a 30-day supply [2]. The coupon is presented at the pharmacy counter and cannot be combined with insurance; the patient pays whichever is lower.

Pfizer does not operate a strong patient assistance program for Cytomel specifically, but the company's patient services line can direct patients to NeedyMeds or the Partnership for Prescription Assistance for low-income Iowans who lack insurance coverage [12]. NeedyMeds lists income-based assistance programs updated regularly; Iowa residents with incomes at or below 200 percent of the federal poverty level may qualify [12].

Mark-Cuban-founded Cost Plus Drugs (costplusdrugs.com) listed generic liothyronine at roughly $6 to $10 per month in early 2026, and the service ships to Iowa addresses [2]. This is a transparent-cost pharmacy model that bypasses PBM markups. A valid Iowa prescription is still required.

GoodRx Gold, the subscription tier, may offer an additional 2 to 5 percent reduction at participating Iowa pharmacies. The annual subscription fee of approximately $99 for an individual plan pays off quickly for patients filling multiple medications.

The HealthRX Iowa Liothyronine Cost Decision Framework helps patients choose the lowest-cost path based on insurance status. Patients with commercial insurance should first check their plan's formulary tier for generic liothyronine. If Tier 1 or Tier 2, use insurance. If Tier 3 or higher, compare the copay to a GoodRx or Cost Plus price and pay cash if cheaper. Iowa Medicaid enrollees should request a prior authorization and, if denied, evaluate the $35 cash-pay generic or a 503A compounded option at approximately $40 per month. Uninsured patients should default to Cost Plus Drugs or GoodRx at an Iowa chain pharmacy, targeting a cost of $10 to $18 per month.

Can Iowa Residents Get Liothyronine via Telehealth?

Telehealth prescribing of liothyronine is fully legal for Iowa residents in 2026. Iowa law permits practitioners licensed in Iowa to prescribe Schedule-exempt medications, including thyroid hormones, via synchronous audio-video telehealth visits without a prior in-person examination, provided the clinician conducts a complete evaluation and documents medical necessity [13].

The Iowa Board of Medicine updated its telehealth rules after the COVID-19 public health emergency to make remote prescribing of non-controlled substances permanent. Liothyronine is not a controlled substance, so no DEA special registration is needed for the prescribing clinician. HealthRX and similar telehealth platforms serving Iowa can order the required thyroid panel (TSH, free T4, free T3) through a nationwide lab network with Iowa draw sites before or at the first visit.

Patients in rural Iowa counties, including those in the northwest and southeast corners of the state that lack endocrinologists within a 60-mile radius, benefit most from telehealth T3 prescribing. The Health Resources and Services Administration designates many Iowa rural counties as Health Professional Shortage Areas for primary care, which means specialist access is limited [14]. Telehealth closes that gap for thyroid management.

A typical telehealth workflow for Iowa liothyronine patients involves a 30 to 45-minute initial video visit, lab review, and a 90-day prescription sent electronically to the patient's preferred Iowa pharmacy. Follow-up visits at 6 to 8 weeks to recheck TSH and free T3 are standard practice [9].

How Is Liothyronine Dosed and Monitored?

Standard liothyronine dosing begins at 5 mcg once or twice daily, with titration upward in 5 mcg increments every 2 to 4 weeks based on TSH and free T3 response. Most adults with hypothyroidism who add T3 to levothyroxine use 5 to 25 mcg of liothyronine per day in divided doses [1].

The Endocrine Society guideline cautions against allowing free T3 to rise above the upper end of the reference range, as supraphysiologic T3 concentrations carry cardiac risk, particularly atrial fibrillation and reduced bone mineral density with long-term exposure [9]. A 2014 JAMA Internal Medicine analysis of claims data (N=39,420) found that patients taking combination T4/T3 therapy had a slightly higher rate of atrial fibrillation compared to levothyroxine monotherapy users, though absolute risk differences were modest [15].

Serum TSH is an imprecise marker for T3 adequacy because liothyronine's shorter half-life produces concentration peaks that suppress TSH transiently. Measuring free T3 approximately 4 hours post-dose (peak) and again pre-dose (trough) gives the prescriber a cleaner picture of the patient's T3 exposure throughout the day. Some clinicians also track resting heart rate and symptom scores using validated instruments such as the ThyPRO-39 questionnaire [16].

Patients starting liothyronine should have baseline TSH, free T4, and free T3 drawn before initiation, then repeat labs at 6 to 8 weeks after any dose change. Annual bone density screening is reasonable for postmenopausal women on long-term T3 therapy, per the American Thyroid Association's clinical guidance [3].

Liothyronine vs. Levothyroxine: When Does T3 Make Clinical Sense in Iowa?

Levothyroxine remains the first-line thyroid hormone replacement for most Iowans with hypothyroidism. Liothyronine is considered when patients have documented, persistent hypothyroid symptoms (fatigue, cognitive slowing, weight gain, cold intolerance) despite TSH values within the normal reference range on optimized levothyroxine dosing.

Genetic testing for DIO2 (deiodinase 2) polymorphisms, which impair intracellular T4-to-T3 conversion, has been proposed as a way to identify patients most likely to benefit from adjunct T3. Jonklaas et al. (2014) reviewed the evidence in the journal Thyroid and concluded that while DIO2 variants are biologically plausible candidates, their clinical utility in selecting T3 therapy remains unproven as of that review [17]. More recent data have not yet changed guideline recommendations.

The practical decision for Iowa patients usually comes down to three questions. Has levothyroxine been adequately trialed (at least 12 months at a dose that keeps TSH between 0.5 and 2.5 mIU/L)? Are symptoms quantifiably affecting quality of life? Is the patient's cardiologic history compatible with T3 exposure? If the answer to all three is yes, a trial of low-dose adjunct liothyronine is clinically defensible based on available evidence [9].

Iowa clinicians should document this reasoning clearly, particularly when submitting prior authorization requests to commercial insurers or requesting Medicaid exceptions.

Iowa-Specific Pharmacy Resources for Liothyronine

Iowa residents have access to several state-specific pharmacy resources that affect liothyronine access and cost. The Iowa Prescription Drug Corporation (IPDC) program, administered through the Iowa Department on Aging, offers drug discount cards to Iowans aged 54 and older who do not qualify for full Medicaid coverage. The IPDC card functions like a commercial PBM discount and may reduce generic liothyronine to $15 to $20 per month at participating pharmacies [18].

The Iowa 340B program network covers Federally Qualified Health Centers (FQHCs) across the state, including UnityPoint Health clinics and Community Health Centers of the Iowa Valley. Patients receiving care at a 340B-covered entity can access dramatically reduced drug prices, sometimes at or below Cost Plus Drug pricing, because 340B entities purchase drugs at the statutory ceiling price [19]. Patients who are uninsured or underinsured and whose primary care comes from an FQHC should ask explicitly whether their pharmacy qualifies for 340B pricing on liothyronine.

The Iowa Board of Pharmacy maintains a public registry of licensed compounding pharmacies in the state. Before filling a compounded liothyronine prescription, patients can verify their pharmacy's license status at the Board's online portal [20]. PCAB-accredited compounding pharmacies in Iowa are limited in number, so patients in rural areas may need to use a licensed mail-order compounding pharmacy that ships to Iowa addresses.